1. Pfizer plans to provide its breast-cancer drug Ibrance for free in the U.K. while the National Institute for Health and Care Excellence, the U.K.’s healthcare cost watchdog, assesses the drug’s cost-effectiveness. In February NICE proposed rejecting the drug. (PharmaTimes)
2. The FDA approved Radicava, Mitsubishi Tanabe Pharma’s treatment for amyotrophic lateral sclerosis. It’s the first approval of a new ALS drug in the U.S. in more than two decades. (Reuters)
3. In the wake of the healthcare bill passed last week by the House of Representatives, people have started to share personal health stories online, based on their concerns about the loss of protection for individuals with pre-existing conditions. They are using the hashtag #IAmAPreexistingCondition. (AP)
4. Nearly half of the judges at this year’s Cannes Lions International Festival of Creativity are women. The percentage of woman judges has grown from 20% in 2013 to 43% in 2017. (AdAge)
5. ICYMI: A Blue Cross Blue Shield Association report blamed drugmakers for the rising costs of prescription drugs, claiming that its plans spent 73% more on drugs in 2016 than in 2010. (Chicago Tribune)
